ArticleJournal of clinical medicine2019

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure.

Naoki Mita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.